Sign in
WF

WEBSTER FINANCIAL CORP (WBS)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 delivered stronger profitability and resilient growth: diluted EPS $1.52 (+17% q/q, +48% y/y) and net income to common $251.7M; revenue $715.8M (+1.6% q/q) as NII rose and noninterest income remained firm .
  • Results beat Wall Street consensus: EPS beat by ~6.6% (1.52 vs 1.43*) and revenue modestly beat ($715.8M vs $712.2M*); NIM dipped 4 bps to 3.44 on seasonal mix and higher cash, partly offset by balance sheet growth .
  • Credit trends improved: provision fell to $46.5M (from $77.5M in Q1); net charge-offs declined to 27 bps annualized; NPLs fell ~5% q/q with allowance coverage at 135% of NPLs .
  • Guidance nudged up: FY25 NII (non-FTE) raised to $2.47–$2.50B and ETR guided to 20–21% (from ~21% prior), assuming two rate cuts beginning in September .
  • Capital return catalyst: CET1 rose to 11.33%; BoD added $700M buyback capacity (May); company repurchased ~1.5M shares in Q2 at ~$51.69; management expects continued buybacks if organic uses don’t absorb capital .

What Went Well and What Went Wrong

What Went Well

  • EPS and revenue beat, with solid ROA and ROATCE: ROA 1.29% and ROATCE 17.96% on efficiency ratio 45.4% and NIM 3.44% .
    “Our strong operating position and distinctive businesses provide us a lot of flexibility and growth opportunities…” — CEO John Ciulla .
  • Balance sheet growth with stable funding: loans +1.2% q/q to $53.7B; deposits +1.1% q/q to $66.3B; loan-to-deposit ratio held at ~81% .
  • Credit improvement: provision $46.5M (down from $77.5M in Q1); NCOs $36.4M vs $55.0M in Q1; NPLs declined to 1.00% of loans .
    “The inflection point in asset quality…is materializing. Both criticized commercial loans and non-accruals were down.” — CEO .

What Went Wrong

  • NIM compression and deposit competition: NIM fell 4 bps q/q to 3.44; management cited seasonal HSA/public deposit mix shift, higher cash, and modest organic spread compression; deposit pricing remains competitive .
  • Segment revenue softness y/y in Commercial Banking: operating revenue down 6% y/y on lower loan spreads and fees; noninterest expense up on workouts and investments .
  • CRE/healthcare exposures remain focal risks: office and healthcare still represent outsized share of NPLs/classifieds; allowance coverage adequate but portfolio remediation continues .
    Analysts probed rent-regulated multifamily valuations and upcoming maturities; management noted seasoned book, small average sizes, and strong DSCR (1.56x) but ongoing regulatory uncertainty .

Financial Results

MetricQ2 2024Q4 2024Q1 2025Q2 2025
Revenue ($USD Millions)$614.6 (NII $572.3 + Noninterest $42.3) $661.0 $704.8 $715.8
Diluted EPS ($)$1.03 $1.01 (Adj $1.43) $1.30 $1.52
Net Interest Income ($MM)$572.3 $608.5 $612.2 $621.2
Noninterest Income ($MM)$42.3 $52.5 $92.6 $94.7
Net Income ($MM)$181.6 $177.8 $226.9 $258.8
NIM (%)3.39 3.39 3.48 3.44
Efficiency Ratio (%)46.22 44.80 45.79 45.40
  • Estimates vs Actual (Q2 2025): EPS consensus 1.43* vs actual 1.52 (Beat); Revenue consensus $712.2M* vs actual $715.8M (Beat) . Values retrieved from S&P Global.

Segment breakdown (Q2 YoY):

SegmentOperating Revenue Q2’25 ($MM)Operating Revenue Q2’24 ($MM)Noninterest Expense Q2’25 ($MM)PPNR Q2’25 ($MM)Loans/Deposits (End-Q2’25, $B)
Commercial Banking349.1 372.1 108.4 240.8 Loans $41.2; Deposits $16.2
Healthcare Financial Services126.3 119.1 55.5 70.9 Deposits $10.2; Linked AUA $5.8
Consumer Banking237.3 227.1 123.0 114.2 Loans $12.5; Deposits $27.8

KPIs and balance sheet:

KPIQ2 2024Q1 2025Q2 2025
Loans & Leases (Period-end, $B)51.6 53.1 53.7
Deposits (Period-end, $B)62.3 65.6 66.3
CET1 (%)10.59 11.26 11.33
Tangible Common Equity (%)7.18 7.43 7.46
NCO / Avg Loans (Annualized, %)0.26 0.42 0.27
NPLs / Total Loans (%)0.72 1.06 1.00
ACL / NPLs (%)181.48 126.39 135.08
ROA (%)0.96 1.15 1.29
ROATCE (%)14.17 15.93 17.96
Book Value / TBV per share ($)$49.74 / $30.82 $52.91 / $33.97 $54.19 / $35.13

Guidance Changes

MetricPeriodPrevious Guidance (Q4’24/Q1’25)Current Guidance (Q2’25)Change
NII (non-FTE)FY 2025$2.45–$2.50B $2.47–$2.50B Raised lower bound
Effective Tax RateFY 2025~21% 20–21%; expect 21% in H2 Lowered/clarified
NIM (full-year)FY 2025~3.35–3.40% ~3.40%; exit 3.35–3.40% Maintained
Loans (EOP growth)FY 2025+4–5% Maintained (implicit) Maintained
Deposits (EOP growth)FY 2025+4–5% Maintained (implicit) Maintained
ExpensesFY 2025$1.39–$1.41B; Cat 4 prep $15–$20M Maintained (implicit) Maintained
CET1 targetNear term~11% ~11% (LT ~10.5% potential) Maintained
Share repurchaseOngoing$700M authorization (May 1) Q2 repurchases ~1.5M shares at $51.69; more likely if organic uses limited Executing

Earnings Call Themes & Trends

TopicQ4 2024 (Prev)Q1 2025 (Prev)Q2 2025 (Current)Trend
NIM/Deposit costsNIM guide 3.35–3.40%; deposit costs down 16 bps; positive repositioning earn-back NIM 3.48; cycle beta ~33%; Q1 strong, moderation later NIM 3.44; seasonal mix/higher cash; deposit competition elevated Stable-range; modest pressure
CreditNCOs ~30 bps FY; office/healthcare drove 60% Q4 NCOs; inflection mid-2025 Raised recession weighting; criticized loans declined; inflection still mid-’25 Provision down; NPLs and criticized down; NCOs 27 bps Improving
Capital & BuybacksCET1 ~11.5%; expect returns in 2025; 11% near-term target, LT 10.5% Buybacks likely if growth/acquisitions not deployed 1.5M shares repurchased; buybacks likely H2 if organic uses limited Execution underway
HSA/HealthcareAmetros growth; HSA investments/new platform Deposit growth; full product suite rolling into 2026 cycle Legislative expansion: Bronze ACA eligibility; $1–$2.5B deposit opportunity over 5 years Positive structural tailwind
Private credit JV (Marathon)JV expected 2Q start; not in guidance On track; structure set, upside potential Operational realization; loans moved HFS; JV ramping, fees mainly in 2026 Building pipeline
Tech/OperationsRepositioning; strategic investments Cloud-native GL complete; Cat 4 prep spend Cloud GL first quarter of earnings; Cat 4 readiness continuing Foundation strengthening
Macro/Tariffs/RegulatoryTailored supervision hope; CRE activity slow Clients preparing; limited direct tariff exposure No credit impact from tariff proposals; regulation changes may help Neutral-to-positive

Management Commentary

  • “Our strong operating position and distinctive businesses provide us a lot of flexibility and growth opportunities… an advantage that will serve us well as tailwinds accumulate for the banking industry.” — CEO John Ciulla .
  • “We now expect NII of $2.47–$2.50 billion… We expect the full year tax rate will be in the range of 20% to 21%.” — CFO Neal Holland .
  • “There was a discrete benefit from a non-accrual reversal that added two basis points to the NIM… excluding this, NIM would have been 3.42%.” — CFO .
  • “Favorable HSA provisions… potential deposit opportunity over the next five years ranges from $1B to $2.5B.” — President & COO Luis Massiani .
  • “We repurchased 1.5 million shares… if loan growth or tuck-ins don’t materialize, you’ll likely see some level of buyback in the second half.” — CEO .

Q&A Highlights

  • Capital and CET1 targets: Near-term target ~11%; long-term comfortable ~10.5% as environment stabilizes; disciplined deployment across loans, healthcare tuck-ins, then buybacks .
  • NIM outlook mechanics: Expect ~3.4% for FY; minor 1 bp drag from higher cash and expected long-term debt issuance in H2; deposit competition intense, but DDA basing .
  • HSA expansion: Bronze plan eligibility opens new direct-to-consumer channel; incremental marketing/education spend but not material OpEx change; multi-year deposit ramp .
  • Originations: Broad-based strength in C&I and CRE; pipelines improved into H2; sponsor finance activity picking up, aided by Marathon JV .
  • CRE/Regulated multifamily: Portfolio seasoned, small average sizes, strong DSCR (1.56x); regulatory outcomes monitored; limited expected material impact .

Estimates Context

  • Q2 2025 vs consensus: EPS 1.52 vs 1.43* (Beat), Revenue $715.8M vs $712.2M* (Beat). Values retrieved from S&P Global.
  • FY 2025 consensus: EPS 5.89*, Revenue $2.89B*; management’s NII/tax guidance suggests upward bias if credit remains benign and deposit costs ease in H2 . Values retrieved from S&P Global.

Key Takeaways for Investors

  • Positive surprise quality: EPS/revenue beat with improved credit metrics and strong ROATCE; efficiency maintained as investments scale—supports multiple expansion if beats persist .
  • Near-term trade: Watch deposit cost trajectory and NIM exit path (~3.35–3.40%); any DDA rebound or lower rate path could drive upside to NII/NIM vs guidance .
  • Capital return: CET1 >11% plus $700M authorization and demonstrated buybacks suggest continued repurchases in H2 absent outsized loan growth or tuck-ins—stock support/catalyst .
  • Structural tailwinds: HSA legislative changes and Marathon JV create new fee/deposit engines; 2026 fee ramp likely from asset management while deposit growth builds in 2025–2026 .
  • Risk monitoring: CRE office/healthcare remain watch items though improving; allowance coverage robust (135% of NPLs) and NPLs trending down—reduce tail risk perception .
  • Regulatory readiness: Category 4 investments (data, controls, GL) enhance resilience; any easing/tailored supervision could lower required spend and improve returns .
  • Medium-term thesis: Differentiated funding (HSA/Ametros/InterSync) and diversified origination channels position WBS to grow faster than peers through cycles—supporting sustained high-teens ROATCE .

All figures are from company filings/press materials unless marked with an asterisk. Values retrieved from S&P Global.